← Back to all signals

ADMA ADMA BIOLOGICS, INC.

Last updated: Nov 16, 2026

🐻

Execution Consistency

Did the company actually spend money buying back stock in 3+ of the last 4 quarters?

Bought back stock in only 1/3 quarters. Q3 2026: $23M, Q2 2026: $0M, Q1 2026: $0M

🐂

Execution Acceleration

Is the most recent quarter's buyback spend more than 15% above the trailing average?

New buyback activity: $23M after no prior spending

🐻

Buyback vs FCF

What percentage of free cash flow is going to buybacks? Bull: 30%+. Bear: negative FCF or no buybacks.

Negative FCF ($-66M), buybacks not supported by cash flow

🐂

Buyback Intensity

How fast are they shrinking the float? Bull: 2%+ annually. Bear: under 0.5%.

Repurchased 9,164,525 shares = 5.1% of 237,874,496 outstanding (annualized)

🐂

Insider Buying

Are officers and directors buying stock with their own money on the open market?

5 open-market purchases by 2 insiders

  • Grossman Jerrold B () bought 6,400 shares at $7.91 on 2026-05-27
  • Grossman Jerrold B () bought 12,500 shares at $8.01 on 2026-05-12
  • Grossman Jerrold B () bought 12,500 shares at $8.01 on 2026-05-11
  • ELMS STEVE () bought 7,000 shares at $15.39 on 2026-03-06
  • ELMS STEVE () bought 7,000 shares at $15.67 on 2026-03-05
—

Insider-Buyback Convergence

Are both company buybacks and insider buying independently active? Bull when the company is buying back stock in 2+ quarters and insiders have made 2+ open-market purchases.

5 insider purchases but company buybacks inactive

🐻

Insider Net Direction

Over the last 90 days, are insiders net buyers or net sellers on the open market?

Insiders bought $0M, sold $2M in the last 90 days (net selling)

—

Red Flag

Active buyback + insiders net selling 3x+ more than buying. Company cash may be supporting price while insiders exit.

No buyback-insider divergence detected